Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Sarcoidosis is a heterogenous disorder often treated with glucocorticoids. Here the authors show, in an open label, non-randomized, single arm clinical trial involving 10 patients, that treatment with tofacitinib, a Janus kinase inhibitor, is associated with improved clinical symptoms and reduced ac...

Full description

Bibliographic Details
Main Authors: William Damsky, Alice Wang, Daniel J. Kim, Bryan D. Young, Katelyn Singh, Michael J. Murphy, Joseph Daccache, Abigale Clark, Ruveyda Ayasun, Changwan Ryu, Meaghan K. McGeary, Ian D. Odell, Ramesh Fazzone-Chettiar, Darko Pucar, Robert Homer, Mridu Gulati, Edward J. Miller, Marcus Bosenberg, Richard A. Flavell, Brett King
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-30615-x

Internet

https://doi.org/10.1038/s41467-022-30615-x

Similar Items